Key Takeaways:
Eli Lilly's GLP-1 portfolio generated $15.8 billion in Q1 2026, outpacing Novo Nordisk's $14.2 billion as the two drugmakers jockey for dominance in obesity and diabetes.
"Lilly's combination of first-mover advantage with Foundayo and a deep next-generation pipeline creates a durable lead," Sam Goldstein, healthcare analyst at Edgen, said.
Lilly's Cardiometabolic Health unit accounted for 80% of total Q1 revenue of $19.8 billion, while Novo Nordisk's Diabetes and Obesity segment contributed 94% of its quarterly sales. The Zacks Consensus Estimate projects Lilly's 2026 revenue will rise 31.6% year over year, with EPS growing 42.7% to $34.55. Novo Nordisk faces a 4.8% revenue decline and a 14.7% EPS drop to $3.38, reflecting pricing pressure and weaker prescription trends for injectable GLP-1s.
The divergence has widened Lilly's market capitalization past $1 trillion, making it the world's largest drugmaker, while Novo Nordisk shares have fallen 23.3% over the past year. Lilly trades at 28.4 times forward earnings, nearly double Novo Nordisk's 14.9 multiple, reflecting investor confidence in its pipeline breadth and growth trajectory.
Foundayo vs. Wegovy Pill: The Oral GLP-1 Battle
Lilly's Foundayo, approved in the US in April 2026, offers GLP-1 therapy in pill form and is rapidly gaining insurance coverage through major pharmacy benefit managers. Novo Nordisk launched its oral Wegovy pill in January 2026 after December 2025 FDA approval, capturing an early lead with more than 3 million prescriptions written since launch. Lilly expects to launch Foundayo in most international markets during 2027, while Wegovy pill received EU approval last week, potentially widening Novo Nordisk's geographic head start.
Pipeline Depth Separates the Two
Lilly's retatrutide, a triple agonist targeting GLP-1, GIP and glucagon pathways, demonstrated approximately 28% weight loss in late-stage studies. The company plans to seek approval for obesity and knee osteoarthritis pain in 2026. Novo Nordisk's CagriSema injection, a fixed-dose combination of cagrilintide and semaglutide, faces an FDA decision in the fourth quarter of 2026 after a December 2025 filing. Disappointing clinical results from some of Novo Nordisk's next-generation obesity programs have shaken investor confidence, while Lilly has announced more than $20 billion in biotech acquisitions this year, including the $2.8 billion purchase of AtaiBeckley to strengthen its neuroscience pipeline.
Lilly's premium valuation — 28.4 times forward earnings versus the industry average of 18.9 times — reflects expectations that its pipeline can sustain growth beyond the current GLP-1 cycle. Novo Nordisk trades below its five-year average multiple, signaling skepticism about its ability to defend market share as competition intensifies from Amgen, Roche, AstraZeneca and Viking Therapeutics. Lilly's dividend yield of 0.6% trails Novo Nordisk's 3.5%, but the growth differential favors the US drugmaker. Investors will watch Lilly's retatrutide approval filing later this year and Novo Nordisk's CagriSema FDA decision in the fourth quarter as the next catalysts that could widen or narrow the gap.
This article is for informational purposes only and does not constitute investment advice.
